ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025

The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and […]

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025 Read Post »

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025 

A review recently published in the European Respiratory Journal Open Research provides the latest evidence on drug- and toxin-associated pulmonary arterial hypertension, offering clinicians updated guidance on recognition, diagnosis, and management of this pulmonary arterial hypertension subtype (see below for the most recent pulmonary arterial hypertension classification, at 1.3) The first World Health Organization (WHO)

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025  Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025

Pulmonary veno-occlusive disease (PVOD) is a rare, severe World Health Organisation Group 1 pulmonary arterial hypertension (PAH) subtype with poor survival. pulmonary arterial hypertension-targeted vasodilators can cause life-threatening pulmonary edema in Pulmonary veno-occlusive disease, underscoring the need for diagnostic tools to distinguish it from other pulmonary arterial hypertension subtypes The findings of a study recently

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025 Read Post »

Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025

The 6th “Journées du Réseau Français de l’Hypertension Pulmonaire” (JRF-HTP), held in October 2024, provided a review of the evolving landscape in pulmonary hypertension (PH). The meeting brought together clinicians and researchers to exchange on the most recent scientific, clinical, and organizational advances in pulmonary hypertension. We are proud that a patient advocate was included as co-author,

Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025 Read Post »

Tacrolimus in Solid Organ Transplantation: A 30-Year Journey, Transplantation, March 2021

Tacrolimus (FK506), discovered in 1984 from Japanese soil fungus, revolutionized organ transplantation. Dr. Thomas Starzl’s pioneering work at the University of Pittsburgh demonstrated dramatic improvements over cyclosporine: liver graft survival increased from 65.5% to 86.2%, with rejection rates dropping to 1-2%. The Food and Drug Administration (FDA) approval followed for liver (1994), kidney (1997), and

Tacrolimus in Solid Organ Transplantation: A 30-Year Journey, Transplantation, March 2021 Read Post »

Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease (PH-CHD), Expert Review of Respiratory Medicine, October 30, 2025

Pulmonary hypertension associated with congenital heart disease (PAH-CHD) is one of the most common causes of pulmonary hypertension in children. Patients fall into different subgroups, each requiring specific treatment approaches. According to an article recently published in the Expert Review of Respiratory Medicine current management is clear for two groups: The challenge The management of

Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease (PH-CHD), Expert Review of Respiratory Medicine, October 30, 2025 Read Post »

Lung Transplant Allocation System Challenges for Pulmonary Arterial Hypertension (PAH) Patients, Letter to the Editor, Transplant International, October 28, 2025

Pulmonary arterial hypertension patients face unique challenges in lung transplantation. Unlike patients with other lung diseases, they often have relatively normal lung function tests but are in critical condition due to heart failure. This means they receive low priority scores in the standard Lung Allocation Score (LAS) system, which was designed primarily for patients with

Lung Transplant Allocation System Challenges for Pulmonary Arterial Hypertension (PAH) Patients, Letter to the Editor, Transplant International, October 28, 2025 Read Post »

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025

Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. A study conducted at the at the University of Utah Pulmonary Hypertension Center compared 263 pulmonary arterial hypertension patients from urban versus rural areas treated in the period 2020-2024. Similar at baseline: Important differences emerged: Conclusion: Despite similar care delivery and

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025 Read Post »

Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute (PVRI), April 2025

A modified Delphi consensus was conducted by the Pulmonary Vascular Research Institute (PVRI) Lung Transplantation Workstream, involving 29 international experts on pulmonary arterial hypertension (PAH) and lung transplantation. The process generated consensus ( mean scores >_2.5 on Likert scale ) across 141 out of 223 statements relating to when to refer pulmonary arterial hypertension patients

Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute (PVRI), April 2025 Read Post »

Latest edition on the Council of Europe’s European Directorate for the Quality of Medicines and HealthCare (EDQM) Newsletter Transplant 2025 is now available

The Council of Europe’s EDQM (European Directorate for the Quality of Medicines and HealthCare) Newsletter Transplant provides regular updates on transplantation-related developments across Europe. It covers policy, regulation, quality standards, and best practices related to organ donation, allocation, and transplant safety, ensuring harmonisation across European Union member states. Additionally, the newsletter shares news on scientific

Latest edition on the Council of Europe’s European Directorate for the Quality of Medicines and HealthCare (EDQM) Newsletter Transplant 2025 is now available Read Post »

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025

Tacrolimus therapeutic drug monitoring is challenging due to high inter- and intra-patient variability. A prospective randomized controlled trial was conducted by researchers at the University Hospital in Leuven, Belgium, on 293 de novo kidney transplant recipients during the first 14 days post-transplant. A fully automated Model-informed precision dosing (MIPD) application (1) was integrated into the

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025 Read Post »

GLP-1 receptor agonists linked to lower mortality, respiratory failure in pulmonary arterial hypertension, Healio News, October 23, 2025

A recent article in Healio news by Isabella Hornick summarises a study titled “Exploring the potential benefits of GLP-1 receptor agonists in pulmonary arterial hypertension: Insights from a large database study”, which was presented at the CHEST Annual Meeting October 19-22, 2025 in Chicago. GLP-1 receptor agonists (Glucagon-Like Peptide-1) are commonly used for diabetes and

GLP-1 receptor agonists linked to lower mortality, respiratory failure in pulmonary arterial hypertension, Healio News, October 23, 2025 Read Post »

Phenotyping of patients with mild pulmonary hypertension, Open Heart journal, October 10, 2025

A study on the importance of phenotyping patients with mild pulmonary hypertension was publslhed on the Open Heart journal on October 10, 2025. They found that most patients with mild precapillary pulmonary hypertension have underlying comorbidities rather than early-stage pulmonary arterial hypertension. Stroke volume index emerged as the key independent predictor of prognosis. Survival was

Phenotyping of patients with mild pulmonary hypertension, Open Heart journal, October 10, 2025 Read Post »

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025

A network meta-analysis conducted by researchers at the Cleveland Clinic Abu Dhabi, published in the October 2025 edition of Frontiers in Medicine, compared the efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension (PAH) by synthesizing data from 32 studies, comprising 24 randomised controlled trials, three open-label trials,and five cohort studies, with a cumulative

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025 Read Post »

New pre-clinical study shows that stem cell fluid may reduce signs of pulmonary arterial hypertension in rat and cell models, Journal of Cellular Physiology, October 2025

A new pre-clinical study shows that stem cell-derived conditioned medium (iPSC-CM)—the liquid remaining after stem cells are cultured—reduces signs of pulmonary arterial hypertension in rat and cell models. In pulmonary arterial hypertension rats treated with daily iPSC-CM infusions, researchers observed reduced blood pressure in the right ventricle, decreased heart enlargement, and thinner pulmonary arterial walls.

New pre-clinical study shows that stem cell fluid may reduce signs of pulmonary arterial hypertension in rat and cell models, Journal of Cellular Physiology, October 2025 Read Post »

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis, New England Journal of Medicine, September 30, 2025

The phase 3 HYPERION trial on sotatercept enrolled 320 adults with newly diagnosed pulmonary arterial hypertension (within 1 year of diagnosis) at intermediate or high risk who were already on double or triple background therapy. Patients were randomized to receive add-on subcutaneous sotatercept or placebo every 21 days. The trial stopped early due to compelling

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis, New England Journal of Medicine, September 30, 2025 Read Post »

Anticoagulation and Survival in Pulmonary Arterial Hypertension: Findings from Large French Registry (1.500+ patients), Journal of the American College of Cardiology, September 30, 2025

Despite historical use, the role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. The goal of a study whose findings were published in the Journal of the American College of Cardiology on September 30, 2025, was to examine the association between anticoagulant

Anticoagulation and Survival in Pulmonary Arterial Hypertension: Findings from Large French Registry (1.500+ patients), Journal of the American College of Cardiology, September 30, 2025 Read Post »

Extracorporeal Photopheresis: Emerging Role in Transplantation and Beyond, Transplantation Direct, September 2025

A newly published review in Transplantation Direct explores the growing significance ofextracorporeal photopheresis (ECP), a therapy that modulates immune responses usingpatients’ own treated blood cells. The article, authored by Panagiotis Parsonidis, MSc, and Prof. Thomas Wekerle of the Medical University of Vienna, Austria, highlights extracorporeal photopheresis’s established safety record while pointing to future opportunities for

Extracorporeal Photopheresis: Emerging Role in Transplantation and Beyond, Transplantation Direct, September 2025 Read Post »

TRANSLATE »
Scroll to Top